Feifei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Feifei Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anchen Zhang
Department of Cardiac Surgery, Institute of Cardiovascular Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication - Chen Wang
China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication - Cuiting Zheng
State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
1 shared publication Haiyong Peng
State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
1 shared publication- Hongbing Zhang
State Key Laboratory of Medical Molecular Biology, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
1 shared publication - Hongfei Wang
Department of Cardiac Surgery, Institute of Cardiovascular Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 19 August 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-16
Polo-like kinase 1 promotes pulmonary hypertension
Background: Pulmonary hypertension (PH) is a lethal vascular disease with limited therapeutic options. The mechanistic connections between alveolar hypoxia and PH are not well understood. The aim of this study was to investigate the role of mitotic regulator Polo-like kinase 1 (PLK1) in PH development.Methods: Mouse lungs along with human pulmonary arterial smooth muscle cells and endothelial cells were used to investigate the effects of hypoxia on PLK1. Hypoxia- or Sugen5416/hypoxia was applied to induce PH in mice.Plk1heterozygous knockout mice and PLK1 inhibitors (BI 2536 and BI 6727)-treated mice were checked for the significance of PLK1 in the development of PH.Results: Hypoxia stimulated PLK1 expression through induction of HIF1α and RELA. Mice with heterozygous deletion ofPlk1were partially resistant to hypoxia-induced PH. PLK1 inhibitors ameliorated PH in mice.Conclusions: Augmented PLK1 is essential for the development of PH and is a druggable target for PH.
- 19 August 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-16
Open AccessPolo-like kinase 1 promotes pulmonary hypertension
Background: Pulmonary hypertension (PH) is a lethal vascular disease with limited therapeutic options. The mechanistic connections between alveolar hypoxia and PH are not well understood. The aim of this study was to investigate the role of mitotic regulator Polo-like kinase 1 (PLK1) in PH development.Methods: Mouse lungs along with human pulmonary arterial smooth muscle cells and endothelial cells were used to investigate the effects of hypoxia on PLK1. Hypoxia- or Sugen5416/hypoxia was applied to induce PH in mice.Plk1heterozygous knockout mice and PLK1 inhibitors (BI 2536 and BI 6727)-treated mice were checked for the significance of PLK1 in the development of PH.Results: Hypoxia stimulated PLK1 expression through induction of HIF1α and RELA. Mice with heterozygous deletion ofPlk1were partially resistant to hypoxia-induced PH. PLK1 inhibitors ameliorated PH in mice.Conclusions: Augmented PLK1 is essential for the development of PH and is a druggable target for PH.